There were no significant differences in gender, age, hypertension, dyslipidemia, smoking, drinking, type of coronary heart disease, number of lesions, number of stents implanted, the total length of stent implanted, the minimum diameter of the stent, and insulin use between the dapagliflozin group and the nondapagliflozin group (P > 0.05), and it was comparable, as shown in Table 1. This evidence concerns the gene INS and coronary artery disorder.